Igene Biotechnology Stock Buy Hold or Sell Recommendation
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Igene Biotechnology is 'Strong Sell'. Macroaxis provides Igene Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IGNE positions.
Check out Igene Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Igene and provide practical buy, sell, or hold advice based on investors' constraints. Igene Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Igene |
Execute Igene Biotechnology Buy or Sell Advice
The Igene recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Igene Biotechnology. Macroaxis does not own or have any residual interests in Igene Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Igene Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Igene Biotechnology Trading Alerts and Improvement Suggestions
| Igene Biotechnology generated a negative expected return over the last 90 days | |
| Igene Biotechnology has some characteristics of a very speculative penny stock | |
| Igene Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.96 M. Net Loss for the year was (140.75 K) with profit before overhead, payroll, taxes, and interest of 1.02 M. | |
| Igene Biotechnology currently holds about 269.29 K in cash with (97.05 K) of positive cash flow from operations. |
Igene Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Igene Biotechnology or Chemicals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Igene Biotechnology's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Igene pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Igene Biotechnology Volatility Alert
At this time Igene Biotechnology exhibits very low volatility. You can indeed make money on Igene instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Igene Biotechnology Fundamentals Vs Peers
Comparing Igene Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Igene Biotechnology's direct or indirect competition across all of the common fundamentals between Igene Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Igene Biotechnology or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Igene Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Igene Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Igene Biotechnology to competition |
| Fundamentals | Igene Biotechnology | Peer Average |
| Return On Asset | -0.0821 | -0.14 |
| Operating Margin | (124.22) % | (5.51) % |
| Current Valuation | 1.1 M | 16.62 B |
| Shares Outstanding | 1.57 B | 571.82 M |
| Shares Owned By Institutions | 0.47 % | 39.21 % |
| Price To Earning | (0.10) X | 28.72 X |
| Price To Sales | 2.28 X | 11.42 X |
| Revenue | 3.96 M | 9.43 B |
| Gross Profit | 1.02 M | 27.38 B |
| EBITDA | (426.98 K) | 3.9 B |
| Net Income | (140.75 K) | 570.98 M |
| Cash And Equivalents | 269.29 K | 2.7 B |
| Current Ratio | 1.15 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (97.05 K) | 971.22 M |
| Earnings Per Share | (0) X | 3.12 X |
| Number Of Employees | 18 | 18.84 K |
| Beta | -2.8 | -0.15 |
| Market Capitalization | 10.96 K | 19.03 B |
| Total Asset | 4.76 M | 29.47 B |
| Retained Earnings | (54.86 M) | 9.33 B |
| Working Capital | 312 K | 1.48 B |
| Current Asset | 2.44 M | 9.34 B |
| Current Liabilities | 2.13 M | 7.9 B |
| Z Score | -15.4 | 8.72 |
| Annual Yield | 0.04 % | |
| Net Asset | 4.76 M |
About Igene Biotechnology Buy or Sell Advice
When is the right time to buy or sell Igene Biotechnology? Buying financial instruments such as Igene Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Igene Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run IT Thematic Idea Now
IT
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Igene Pink Sheet
Igene Biotechnology financial ratios help investors to determine whether Igene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Igene with respect to the benefits of owning Igene Biotechnology security.